Can AI hear Alzheimer’s disease before you can?
A new review from Redenlab and the University of Melbourne examines how machine learning is turning everyday speech into scalable tool for early Alzheimer’s prescreening.
Our new review, published in Future Neurology, examines 45 studies using machine learning to analyse speech and language in early Alzheimer’s disease and mild cognitive impairment (MCI).
The core finding is clear: speech carries a cognitive signature. Machine learning models can detect meaningful patterns in pauses, speech rate, prosody, word choice, sentence structure and discourse organisation, changes that may reflect early disruption across memory, executive function, language and speech motor systems, often before symptoms are obvious in a clinical setting.
This is what makes speech a compelling prescreening candidate. It can be collected remotely, repeated frequently, and analysed by AI to surface subtle patterns that routine clinical workflows can miss, making it a compelling candidate as a digital biomarker.
But promising algorithms aren’t enough on their own. Translating this research into practice will require:
- Longitudinal validation across time, not single timepoints
- External replication across independent cohorts
- Multilingual testing to ensure models generalise
- Integration with biological markers, including blood based and amyloid related endpoints
For Alzheimer’s disease trials, AI-enabled speech biomarkers may help support lower burden screening, participant enrichment, remote monitoring, and more clinically meaningful measurement of change over time.
Speech will not replace clinical assessment or biological markers. But it may become a powerful digital layer, connecting pathology, cognition and everyday communication in a way that’s scalable and patient centred.
